The potential introduction of AI into the clinical ART world holds both tremendous benefits and ethical complexities. If approved for clinical application, the use of AI to separate high-quality embryos from those that are chromosomally abnormal might save healthcare professionals time and effort by processing and interpreting more data with greater depth and precision. This might, in turn, improve the efficiency of ART and subsequent pregnancy outcomes, treatment options and care for patients with infertility. At a societal level, it could minimise healthcare costs by reducing the use of unnecessary testing or treatment.
Download PDF:
Journal Area:
None